A federal Class I recall, a Louisiana plaintiff describing hours of electrical shocks, and a securities class action exposing a corporate crisis — the Inspire sleep apnea lawsuit landscape is accelerating fast in 2026. If you received an Inspire Upper Airway Stimulation (UAS) implant and experienced painful stimulation, device failure, or required revision surgery, you may be standing at the opening of one of the most significant medical device mass torts of this decade. This litigation tracker breaks down everything injured patients need to understand right now, before a Multi-District Litigation (MDL) is established and the legal landscape shifts.
What Is the Inspire Sleep Apnea Device and Why Is It Under Legal Scrutiny?
The Inspire Upper Airway Stimulation system first received FDA approval in 2014 as a surgically implanted alternative to CPAP therapy for patients with obstructive sleep apnea (OSA). The system consists of three components: an implantable pulse generator (IPG) surgically placed in the chest, a stimulation lead that activates the hypoglossal nerve to keep the airway open during sleep, and a sensing lead that monitors breathing patterns. For many patients living with moderate-to-severe OSA, it represented a genuine leap forward in treatment options.
That promise, however, has been thrown into serious doubt. In June 2024, the FDA issued a Class I recall — the agency’s most serious recall category, reserved for situations where a product may cause serious injury or death — targeting the Inspire IV implantable pulse generator, Model 3028. The recall identified a manufacturing defect causing electrical leakage in the sensing circuit, a flaw that the FDA warned could result in understimulation, loss of therapy, inappropriate stimulation, painful stimulation, perceived shocking sensations, and death. The recall covered 32 devices worldwide, identified by UDI 0855728005915.
For patients already living with this device, those are not abstract risks. They are documented outcomes — and they are the foundation of growing Inspire sleep apnea lawsuit filings in 2026. If you are evaluating what your injuries may be worth, a medical malpractice calculator can provide an early benchmark for defective medical device harm.
FDA Class I Recall: The Legal and Medical Significance
Not all recalls are created equal. A Class I recall designation from the FDA means the agency has determined that use of the product creates a reasonable probability of serious adverse health consequences or death. This classification is critical for personal injury litigation because it establishes a documented, government-acknowledged product danger — one that manufacturers cannot easily dispute in court.
The recall of Inspire IV Model 3028 stems from a manufacturing defect in the sensing circuit that allows electrical leakage to occur. When this leakage reaches the stimulation lead, it can deliver unintended, uncontrolled electrical current directly into the patient’s body. The FDA’s own MAUDE (Manufacturer and User Facility Device Experience) database continues to show active adverse event reports for Inspire devices, with entries updated as recently as July 31, 2026 — a clear signal that this is not a resolved issue.
The ongoing nature of MAUDE reporting is significant. It means real patients are still experiencing real harm. It means the evidentiary record is still being built. And it means attorneys filing Inspire sleep apnea lawsuits today have an expanding body of FDA-documented evidence to work with. Legal observers watching this litigation are drawing direct comparisons to the early stages of hernia mesh and IVC filter litigation — both of which began with individual cases, expanded to MDL consolidation, and ultimately produced billions in settlements.
The Luquette Lawsuit: First Major Personal Injury Filing in 2026
The clearest signal that individual Inspire sleep apnea lawsuit filings are gaining momentum is the February 19, 2026 complaint filed by Blake Luquette in Louisiana. According to reporting by AboutLawsuits.com in April 2026, Luquette alleges his Inspire implant malfunctioned catastrophically — delivering repeated, uncontrolled electrical shocks for hours, causing severe injuries that ultimately required surgical removal of the device.
The allegations in Luquette v. Inspire Medical Systems are legally significant because they track directly against the precise failure modes the FDA identified in its recall: inappropriate and painful electrical stimulation. The complaint raises claims of defective design, inadequate testing, and failure to warn patients about the risk of excessive electrical stimulation. These are the foundational pillars of a product liability mass tort, and they signal that plaintiff attorneys have already done the pre-suit investigative work needed to pursue these cases aggressively.
Reported patient complications extend beyond electrical shocks. Patients have reported infection, nerve damage, chronic pain from stimulation, device migration, and complete device failure requiring surgical revision. For patients who have suffered any of these outcomes, understanding the personal injury settlement calculator factors — including medical expenses, lost wages, pain and suffering, and future care costs — is a practical first step toward assessing legal options.
Inspire Medical’s Corporate Crisis: The Securities Class Action
The legal troubles surrounding Inspire Medical Systems are not limited to product liability. On November 6, 2025, a securities class action — City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems — was filed in the District of Minnesota. The lawsuit alleges that Inspire Medical misled investors about the anticipated demand for its next-generation Inspire V device, causing a staggering 32% single-day stock collapse and a greater than 80% reduction in the company’s 2025 earnings guidance.
For mass tort observers, this securities litigation is deeply relevant context. A company simultaneously facing a Class I recall on its flagship implantable device, mounting personal injury claims, and a securities fraud lawsuit alleging misrepresentation to investors is a company under extraordinary financial and reputational pressure. That pressure matters when it comes to the eventual resolution of Inspire sleep apnea lawsuit claims — companies in crisis are more motivated to negotiate, but they are also more likely to delay if their financial position deteriorates.
Inspire Sleep Apnea Lawsuit Key Facts at a Glance
| Category | Detail | Source / Date |
|---|---|---|
| FDA Recall Classification | Class I (most serious) — risk of serious injury or death | FDA, June 2024 |
| Device Recalled | Inspire IV Implantable Pulse Generator, Model 3028 (UDI 0855728005915) | FDA Recall Database |
| Devices Covered by Recall | 32 devices worldwide | respiratory-therapy.com, November 2024 |
| Recall Defect | Manufacturing defect causing electrical leakage in sensing circuit | FDA Recall Notice, 2024 |
| FDA Risks Identified | Understimulation, loss of therapy, inappropriate stimulation, painful stimulation, death | FDA Recall Notice, 2024 |
| MAUDE Adverse Events | Active reports updated through July 31, 2026 | FDA MAUDE Database, 2026 |
| First Major PI Lawsuit Filed | Luquette v. Inspire Medical (Louisiana) — February 19, 2026 | AboutLawsuits.com, April 2026 |
| Securities Class Action Filed | City of Pontiac v. Inspire Medical — November 6, 2025 (D. Minnesota) | Bloomberg Law / BusinessWire, November 2025 |
| Stock Drop (Inspire V Launch Failure) | 32% single-day decline; >80% cut to 2025 earnings guidance | BusinessWire, November 2025 |
| MDL Status | No MDL consolidated as of 2026; individual suits active | lawfold.com, June 2026 |
| Global Settlement | None announced as of 2026 | lawfold.com, June 2026 |
Where This Litigation Stands in 2026: Pre-MDL Inflection Point
As of 2026, the Inspire sleep apnea lawsuit landscape has not yet reached MDL consolidation. Legal analysts tracking the litigation — including commentary published by lawfold.com in June 2026 — note that this mirrors the early trajectory of both hernia mesh and IVC filter litigation, two of the largest medical device mass torts in U.S. legal history. In both of those cases, individual lawsuits were filed first, plaintiff attorneys built evidentiary records, and eventually the case volume triggered federal MDL consolidation in a single district court.
That pre-MDL window is significant for two reasons. First, early filers often have more direct attorney attention and negotiating leverage before a global settlement framework compresses individual case value. Second, statutes of limitations in many states run from the date a patient knew or reasonably should have known of their injury — meaning waiting for an MDL to form before filing could permanently bar a claim. Justia’s state law resources provide a useful starting point for understanding the product liability statute of limitations in your specific state.
The comparison to hernia mesh is particularly instructive. Plaintiffs in those cases who filed during the pre-MDL window — before case management orders, plaintiff steering committees, and global settlement negotiations defined the landscape — retained significantly more control over their individual claims. The same dynamic is playing out now in Inspire sleep apnea lawsuit litigation.
In the tragic event that a loved one died due to an Inspire device malfunction — a risk explicitly identified in the FDA’s Class I recall notice — families may have claims that extend beyond product liability. A wrongful death calculator can help surviving family members begin to understand the financial scope of potential recovery under applicable state law.
Who Qualifies to File an Inspire Sleep Apnea Lawsuit?
If you received an Inspire Upper Airway Stimulation implant and experienced any of the following, you may be a qualifying claimant in the ongoing Inspire sleep apnea lawsuit litigation:
- Electrical shocks or painful stimulation — including sudden, unexpected, or prolonged electrical sensations from the implant
- Inappropriate device stimulation — stimulation that occurs outside normal therapy parameters or outside sleep periods
- Loss of therapy / device failure — the device stopped providing effective OSA treatment due to malfunction
- Revision surgery — surgical removal or replacement of the Inspire device due to malfunction, infection, or injury
- Infection — implant site infection requiring medical treatment or hospitalization
- Nerve damage — hypoglossal nerve injury or other neurological complications linked to the device or its malfunction
- Device migration — movement of the implanted components from their original surgical placement
- Death of a family member — wrongful death claims where a device malfunction contributed to a fatal outcome
The specific device most directly implicated is the Inspire IV Model 3028 covered by the June 2024 Class I recall, but adverse event reports in the FDA MAUDE database encompass a broader range of Inspire device models. Cornell Law School’s Legal Information Institute provides a clear overview of how product liability law applies to defective medical devices if you want to understand the legal framework before speaking with an attorney.
Frequently Asked Questions About the Inspire Sleep Apnea Lawsuit
What exactly was recalled and why?
The FDA issued a Class I recall in June 2024 for the Inspire IV implantable pulse generator, Model 3028 (UDI 0855728005915). The recall was triggered by a manufacturing defect that causes electrical leakage in the device’s sensing circuit. That leakage can cause the device to deliver unintended, uncontrolled electrical current to surrounding tissue and the stimulation lead, resulting in painful stimulation, inappropriate shocks, loss of sleep apnea therapy, and — in the most serious cases — death. The recall covered 32 devices worldwide and represents the FDA’s most serious recall classification.
Has there been a global settlement of Inspire sleep apnea lawsuits?
No. As of 2026, no global settlement has been announced in the Inspire sleep apnea lawsuit litigation. Cases have not yet been consolidated into a federal MDL. Individual product liability lawsuits, like the Luquette case filed in Louisiana in February 2026, represent the primary litigation vehicle at this stage. Legal observers compare this to the early stages of hernia mesh and IVC filter litigation — before MDL consolidation and global settlement negotiations defined the resolution landscape. This means the window to file an individual claim with maximum leverage remains open.
What injuries or damages can I seek compensation for?
Qualifying injuries in the Inspire sleep apnea lawsuit context include electrical shocks, painful or inappropriate stimulation, device failure requiring revision surgery, infection, nerve damage, device migration, and loss of OSA therapy. Compensable damages in a product liability lawsuit typically include past and future medical expenses (including the cost of surgical removal and revision), lost wages and diminished earning capacity, pain and suffering, emotional distress, and — in cases where a family member died — wrongful death damages including loss of consortium and funeral costs. The precise value of any individual claim depends on the severity of injuries, state law, and the specific evidence available.
How long do I have to file an Inspire sleep apnea lawsuit?
Product liability statutes of limitations vary by state, typically ranging from two to four years. Critically, most states apply a “discovery rule” — meaning the clock starts running from the date you knew or reasonably should have known that your injury was caused by the Inspire device. For patients who only recently learned of the FDA recall or connected their symptoms to the device, this rule may extend the filing window. However, waiting to see whether an MDL forms before taking action carries real legal risk: if your limitations period expires, your claim may be permanently barred. Consulting with a mass tort attorney promptly is strongly advisable.
What is an MDL and how does it affect my Inspire lawsuit?
A Multi-District Litigation (MDL) is a federal procedural mechanism that consolidates similar cases from across the country into a single district court for coordinated pre-trial proceedings, including discovery and bellwether trials. MDL consolidation does not merge your case — you retain your individual claim — but it streamlines the litigation and typically accelerates global settlement negotiations. As of 2026, no MDL has been established for Inspire sleep apnea lawsuit claims, but legal analysts consider MDL consolidation likely if case volume grows, mirroring the trajectory of hernia mesh and IVC filter mass torts. Filing an individual lawsuit now preserves your rights regardless of whether an MDL is eventually formed.
This content is for general informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a licensed attorney in your jurisdiction.
Related reading: EnVista Cataract Lens TASS Lawsuit: Damages Calculator & Compensation When Manufacturing Defects Cause Permanent Eye Inflammation
Related reading: EMR Audit Trails In Medical Malpractice: How Electronic Records Win (Or Sink) Your Claim In 2026
Related reading: EMR Audit Trails In Medical Malpractice: How Electronic Records Win (Or Sink) Your Claim In 2026
Related reading: New York’s CPLR 4545 Collateral Source Offset: The Post-Verdict Hearing That Can Silently Erase Wrongful Death Damages After The Jury Goes Home
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.